China NMPA to Create Market Exclusivity for Pediatric and Rare Disease Drugs

The exclusivity pledge matters less as a new incentive than as a signal that Chinese regulators are formalizing the trade-off between innovation rewards and pricing pressure in areas where patient populations are small. Pairing it with trial-data protection and early guidance for novel targets suggests a broader effort to keep pediatric, rare-disease and frontier research — including brain-computer interfaces — inside China rather than developed abroad. The open question is how the exclusivity window will be scoped and enforced relative to the price negotiations that govern hospital access.